PRL (Phakic Refractive Lens) implant moves to phase III US myopia trials:
This article was originally published in Clinica
The US FDA has given Medennium the green light to start phase III trials of its intraocular lens for treating myopia. The Phakic Refractive Lens (PRL) is a posterior chamber device that is inserted in a procedure similar to artificial lens insertion in cataract surgery. Unlike other intraocular lens and implantable contact lenses, the device is not fixated in the eye, says the Irvine, California company. The PRL is already available in Europe, where it is distributed exclusively by CIBA Vision, the eye care unit of Novartis.